Research map: Targeting kidney disease in type 1 diabetes: progress and promise

Back to the article

Papers in this map

  1. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus · The Diabetes Control and Complications Trial Research Group · 1993 · 24812 citations · Cited by this paper
  2. The relationship between iron deficiency and thyroid function: findings from a population-based study in Jordan · 2026 · Related
  3. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease · Paul E. Stevens · 2024 · 8239 citations · Cited by this paper
  4. Exploring actions of glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond glucose and obesity control: bone health and osteoporosis · 2026 · Related
  5. The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy · Edmund J. Lewis · 1993 · 5446 citations · Cited by this paper
  6. The effects of levothyroxine monotherapy versus combination therapy on quality of life and patient satisfaction · 2025 · Related
  7. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes · Vlado Perkovic · 2024 · 1826 citations · Cited by this paper
  8. Possible attenuation of gout risk by SGLT-2 inhibitors in patients using thiazide and loop diuretics · 2025 · Related
  9. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial · 1994 · 1670 citations · Cited by this paper
  10. The intersection of education and health: schools as a catalyst for childhood obesity prevention · 2026 · Related
  11. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus · David Z.I. Cherney · 2013 · 1331 citations · Cited by this paper
  12. Plasma vitamin D status and its association with biochemical, clinical and humanistic outcomes in diabetic foot infection patients: a prospective observational study in a tertiary healthcare facility · 2025 · Related
  13. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis · Rajiv Agarwal · 2021 · 1298 citations · Cited by this paper
  14. Moving away from BMI: a new era of diagnostic criteria in obesity · 2025 · Related
  15. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study · Gabriel A Gregory · 2022 · 1158 citations · Cited by this paper
  16. Metabolic aspects of polycystic ovary syndrome · 2026 · Related
  17. Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment · Lennart Tonneijck · 2017 · 896 citations · Cited by this paper
  18. Serum asprosin and its association with bone mineral density, oxidative stress, and osteoprotegerin levels in Pakistani women with postmenopausal osteoporosis · 2025 · Related
  19. Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes · Michael S. Mauer · 2009 · 795 citations · Cited by this paper
  20. Next-generation therapeutics for diabetic kidney disease · 2026 · Related
  21. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial · Hiddo J.L. Heerspink · 2019 · 633 citations · Cited by this paper
  22. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria · Nish Chaturvedi · 1997 · 522 citations · Cited by this paper
  23. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes · Satish K. Garg · 2017 · 421 citations · Cited by this paper
  24. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes · Marcel H.A. Muskiet · 2017 · 405 citations · Cited by this paper
  25. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes · Alessandro Doria · 2020 · 392 citations · Cited by this paper
  26. Decreasing Incidence of Severe Diabetic Microangiopathy in Type 1 Diabetes · Peter Hambak Hovind · 2003 · 377 citations · Cited by this paper
  27. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials · Julio Rosenstock · 2018 · 364 citations · Cited by this paper
  28. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) · Ian H. de Boer · 2022 · 361 citations · Cited by this paper
  29. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial · Erik J.M. van Bommel · 2019 · 359 citations · Cited by this paper
  30. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial · John R. Petrie · 2017 · 356 citations · Cited by this paper
  31. Increased kidney size, glomerular filtration rate and renal plasma flow in short-term insulin-dependent diabetics · Jens Sandahl Christiansen · 1981 · 325 citations · Cited by this paper
  32. The Modern Spectrum of Renal Biopsy Findings in Patients with Diabetes · Shree Gopal Sharma · 2013 · 322 citations · Cited by this paper
  33. The RAAS in the pathogenesis and treatment of diabetic nephropathy · Piero Luigi Ruggenenti · 2010 · 317 citations · Cited by this paper
  34. Estimated GFR: time for a critical appraisal · Esteban Porrini · 2018 · 302 citations · Cited by this paper
  35. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial · Paresh Dandona · 2017 · 295 citations · Cited by this paper
  36. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic Activity · Jana Grune · 2018 · 290 citations · Cited by this paper
  37. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy · Steen Andersen · 2000 · 286 citations · Cited by this paper
  38. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes · Rajiv Agarwal · 2025 · 284 citations · Cited by this paper
  39. Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms · Karen D. Corbin · 2018 · 262 citations · Cited by this paper

Source: OpenAlex (CC0)